Cardiff Oncology Inc
For the period ended Dec 31, 2023. Filed Feb 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 29, 2024
CRDF$0.80+5.3%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
| Year ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Operating activities | ||
| Net loss | $(41,441) | $(38,704) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Loss on disposal of assets | — | 1 |
| Depreciation | 398 | 236 |
| Stock-based compensation expense | 4,509 | 4,256 |
| (Accretion) amortization of (discounts) and premiums on short-term investments, net | (921) | 632 |
| Release of clinical trial funding commitment | — | 139 |
| Changes in operating assets and liabilities: | ||
| Other assets | 108 | (1,148) |
| Accounts receivable and unbilled receivable | 483 | (236) |
| Prepaid expenses and other current assets | 3,169 | (443) |
| Operating lease right-of-use assets | 543 | 545 |
| Accounts payable and accrued expenses | 2,831 | 1,348 |
| Operating lease liabilities | (566) | (404) |
| Other liabilities | — | (42) |
| Net cash used in operating activities | (30,887) | (33,820) |
| Investing activities | ||
| Capital expenditures | (582) | (1,006) |
| Insurance proceeds from casualty loss | — | 114 |
| Maturities of short-term investments | 86,552 | 76,445 |
| Purchases of short-term investments | (70,084) | (91,233) |
| Sales of short-term investments | 20,309 | 53,829 |
| Net cash provided by investing activities | 36,195 | 38,149 |
| Financing activities | ||
| Proceeds from exercise of options | — | 75 |
| Net cash provided by financing activities | — | 75 |
| Net change in cash and cash equivalents | 5,308 | 4,404 |
| Cash and cash equivalents—Beginning of period | 16,347 | 11,943 |
| Cash and cash equivalents—End of period | $21,655 | $16,347 |
| Supplementary disclosure of cash flow activity: | ||
| Cash paid for taxes | $1 | $2 |
| Acquisition of property and equipment included in accounts payable and accrued liabilities | $16 | $232 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Cumulative preferred stock dividend adjustment | $— | $(414) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.